

Transplantation Ethics: Balancing organ availability and Fairness in Allocation

Roel Jennifer*

Department of Epidemiology, Boston University School of Public Health, Boston, MA, USA

Abstract

Organ transplantation is a life-saving procedure that has helped to improve the quality of life for millions around the world. Advances in medical technology and research have made it possible for people to receive organ transplants from donors, either living or deceased, to replace damaged or diseased organs. However, the demand for organs far exceeds the availability, creating ethical challenges for those involved in the allocation process. Transplantation ethics have evolved over time to address these challenges, trying to balance the need for organ availability with fairness and equity in allocation. This paper will explore the ethical issues associated with organ transplantation, particularly with regard to organ allocation, and how they are addressed in practice.

Keywords: Transplantation; Organ allocation; Transparent

Introduction

Organ transplantation has been a part of medical practice for over 60 years, beginning with the first successful kidney transplant in 1954. Since then, thousands of people have received organ transplants and have benefited from the procedure. However, the success of transplantation has also led to an increased demand for organs [1], particularly as the population ages and the incidence of chronic diseases increases. According to data from the United Network for Organ Sharing (UNOS), as of August 2021 [2], there were 107,987 people on the waiting list for organ transplants in the United States alone, with 87,676 waiting for kidney transplants (UNOS, 2021). Unfortunately, the number of available organs is not enough to meet this demand, and many people die while waiting for a suitable donor organ [3].

Background

One of the key ethical challenges associated with organ transplantation is the allocation of organs. The decision about who receives an organ transplant and when is complex and involves many factors, including medical urgency, compatibility, and availability of donor organs. Ethical considerations related to allocation include issues of fairness, justice, efficiency, and transparency [4]. The allocation process must be transparent and based on established criteria that are fair and just to all potential recipients.

Ethical principles

- The allocation of organs for transplantation should be guided by ethical principles which ensure that the process is fair, equitable, and transparent. The following principles are commonly used in organ allocation:
 - Justice: The principle of justice requires that the allocation process treats all patients fairly regardless of their socio-economic status, race, gender, or other non-medical factors. Allocation decisions should be based solely on medical factors such as the severity of the illness and the likelihood of success in performing the transplant [5].
 - Autonomy: The principle of autonomy requires that individual patients have the right to make informed decisions about their care. Patients should be informed about the risks and benefits of transplantation, and they should have the right to refuse a transplant or choose to be placed on the waiting list [6].

- Beneficence: The principle of beneficence requires that healthcare providers act in the best interests of their patients. Transplantation should be performed only when it is likely to increase the health and well-being of the patient [7].
- Non-maleficence: The principle of non-maleficence requires that healthcare providers do no harm to their patients. Transplantation should be avoided if it poses excessive risk to the recipient.
- Utility: The principle of utility requires that scarce resources be allocated in a way that maximizes overall benefit to society. Transplantation should be performed when it is likely to produce the greatest overall benefit to society [8].

Organ allocation systems

Organ allocation systems are designed to prioritize recipients based on a set of criteria that takes into account various medical and non-medical factors. There are two main types of allocation systems:

- First-come, first-served: In this system, patients are placed on the waiting list in the order in which they apply for transplantation. This system is based on the principle of justice, which requires that patients be treated equally. However, it does not take into account the severity of the patient's condition or the likelihood of success in performing the transplant. As a result, patients with less severe conditions may receive transplants before those with more severe conditions [9].
- Medical urgency: In this system, patients are prioritized based on the severity of their illness and the likelihood of success in performing the transplant. Patients with more severe conditions are given priority over those with less severe conditions. This system is based on the principles of beneficence and non-maleficence, which require that healthcare providers act in the best interests of their patients [10].

*Corresponding author: Roel Jennifer, Department of Epidemiology, Boston University School of Public Health, Boston, MA, USA, E-mail: james67@gmail.com

Received: 01-Mar-2023, Manuscript No: jcet-23-92546; Editor assigned: 04-Mar-2023, PreQC No: jcet-23-92546 (PQ); Reviewed: 18-Mar-2023, QC No: jcet-23-92546; Revised: 24-Mar-2023, Manuscript No: jcet-23-92546 (R); Published: 30-Mar-2023, DOI: 10.4172/2475-7640.1000160

Citation: Jennifer R (2023) Transplantation Ethics: Balancing organ availability and Fairness in Allocation. J Clin Exp Transplant 8: 160.

Copyright: © 2023 Jennifer R. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Conclusion

Organ transplantation is a life-saving procedure that has helped to improve the quality of life for millions of people around the world. However, the success of transplantation has also led to an increased demand for organs, creating ethical challenges for those involved in the allocation process. Ethical principles such as justice, autonomy, beneficence, non-maleficence, and utility should guide the allocation process to ensure that it is fair, equitable, and transparent. Allocation systems should prioritize patients based on the severity of their illness and the likelihood of success in performing the transplant. While there is no perfect system for allocating organs, the process can be improved

References

1. Swaminathan VV, Uppuluri R, Patel S, Ravichandran N, Ramanan KM, et al. (2020) Matched Family versus Alternative Donor Hematopoietic Stem Cell Transplantation for Patients with Thalassemia Major: Experience from a Tertiary Referral Center in South India. *Biol Blood Marrow Transplant* 26: 1326-1331.
2. Kelta M, Zekri J, Abdelghany E, Rehman JU, Khan ZA, et al. (2018) High-dose chemotherapy and peripheral hematopoietic stem cell transplantation in relapsed/refractory Hodgkin's lymphoma. *Tumori*. 104:471-475.
3. Lucarelli G, Isgrò A, Sodani P, Gaziev J (2012) Hematopoietic stem cell transplantation in thalassemia and sickle cell anemia. *Cold Spring Harb Perspect Med* 2: 118-125.
4. Ni W, Wang W, Hong J, Zhang P, Liu C (2015) A novel histopathologic finding in the Descemet's membrane of a patient with Peters Anomaly: a case-report and literature review. *BMC Ophthalmol* 15: 139.
5. Nischal KK, Naor J, Jay V, MacKeen LD, Rootman DS (2022) Clinicopathological correlation of congenital corneal opacification using ultrasound biomicroscopy. *Br J Ophthalmol* 86: 62-69.
6. Datta I, Mishra S, Mohanty L, Pulikkot S, Joshi PG (2011) Neuronal plasticity of human Wharton's jelly mesenchymal stromal cells to the dopaminergic cell type compared with human bone marrow mesenchymal stromal cells. *Cytotherapy* 13: 918-32.
7. Germain RN (2004) An innately interesting decade of research in immunology. *Nat Med* 10: 1307-1320.
8. Kaufmann SH (2008) Immunology's foundation: the 100-year anniversary of the Nobel Prize to Paul Ehrlich and Elie Metchnikoff. *Nat Immunol* 9(7):705-712
9. Leone P, Solimando AG, Malerba E, Fasano R, Buonavoglia A, et al. (2020) Actors on the Scene: Immune Cells in the Myeloma Niche. *Front Oncol* 10:597-598.
10. Kohler H, Pashov AD, Kieber-Emmons T (2019) Commentary: Immunology's Coming of Age. *Front Immunol* 10:21-75.